Allarity Announces New Phase 2 Protocol For Stenoparib In Advanced Ovarian Cancer, To Focus On Dose Optimization And DRP Selection Criteria; Enrollment Targets Patients With Platinum-Resistant Disease; Study Aims To Enhance Understanding Of Wnt...

BenzingaFeb 6 08:03 ET

Express News | Allarity Therapeutics Inc - Patient Enrollment Expected to Begin in First Half of 2025

ReutersFeb 6 08:00 ET

Allarity Therapeutics Announces Agreement In Principle With SEC To Resolve Investigation Related To 2022 Disclosures On FDA Meetings For NDA On Dovitinib; Settlement Approval Pending

BenzingaJan 30 08:04 ET

Express News | Allarity Therapeutics Inc: Has Reached an Agreement in Principle With the SEC Staff to Resolve the Investigation With Respect to the Co

ReutersJan 30 07:58 ET

Express News | Allarity Therapeutics Inc - Two Patients Exceed 14 Months on Treatment in Phase 2 Trial

ReutersNov 18, 2024 08:00 ET

Express News | Allarity Therapeutics Inc - Maintains Cash Balance of $18.5 Million

ReutersNov 18, 2024 08:00 ET